All
Verzenio Granted Priority Review for Breast Cancer Treatment
October 13th 2017Verzenio (abemaciclib) was granted a priority review to a new drug application (NDA) to be used in combination with an aromatase inhibitor for the frontline treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, according to Eli Lilly and Company, the manufacturer of the drug.
New Maintenance Therapy for Ovarian Cancer Seeks FDA Approval
October 12th 2017The pharmaceutical company Clovis Oncology filed a supplemental new drug application (sNDA) to the FDA for their drug Rubraca (rucaparib) to be used as maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Individualized Treatment Needed for Relapsed, Refractory Multiple Myeloma
October 10th 2017Patients with relapsed/refractory multiple myeloma should be given individualized treatment approaches guided by the biology of their disease, frailty of the patient and other comorbidities, said Natalie S. Callander, M.D., who presented on the topic at the NCCN 12th Annual Congress: Hematologic Malignancies in San Francisco, California.
Smartphone App Aims to Conquer Social Isolation of Young Cancer Survivors
October 9th 2017All too often for these individuals, a once-normal social life is thrown to the wayside and replaced with doctors’ appointments and treatment regimens. Friends and family members may not fully understand what their loved one is going through. A new app is here to help.
Expert Gives an Overview of New Drugs to Treat AML
October 9th 2017For the past four decades, there have been few advances in the treatment field of acute myeloid leukemia (AML). However, in the year 2017, there have been four new drugs approved by the FDA to treat the disease, with even more promising agents in the pipeline.